Maxygen hands out pink slips

Maxygen is laying off 25 workers - 16% of its workforce - as it focuses more of its resources on clinical development and away from early-stage research. The Redwood City, CA-based company plans to ask the FDA next year for approval to start trials on two therapies - interferon alpha and GCSF.

- read this report from the San Francisco Business Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.